APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Disease Control and Prevention Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Disease Control and Prevention Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025205 pages

Choose your research edition.

Industry ResearchDisease Control and Prevention Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Disease Control and Prevention Vaccine Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Disease Control and Prevention Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Disease Control and Prevention Vaccine Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Disease Control and Prevention Vaccine Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Disease Control and Prevention Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Disease Control and Prevention Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Disease Control and Prevention Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Disease Control and Prevention Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Disease Control and Prevention Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Disease Control and Prevention Vaccine market include GSK, Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Pfizer, Daiichi Sankyo, AstraZeneca PLC, Sinovac Biotech Ltd and Serum Institute of India Pvt. Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Disease Control and Prevention Vaccine market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Disease Control and Prevention Vaccine and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Disease Control and Prevention Vaccine revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Disease Control and Prevention Vaccine market.

Disease Control and Prevention Vaccine Segment by Company

GSK

Takeda Pharmaceutical Company Limited

Sanofi

Johnson & Johnson

Pfizer

Daiichi Sankyo

AstraZeneca PLC

Sinovac Biotech Ltd

Serum Institute of India Pvt. Ltd

Panacea Biotec Ltd

Novavax Inc

Mitsubishi Tanabe Pharma Corporation

Merck & Co., Inc

Inovio Pharmaceuticals Inc

Emergent BioSolutions Inc

CSL Limited

Bharat Biotech International

Bavarian Nordic A/S

Astellas Pharma Inc

Abbott Laboratories

Disease Control and Prevention Vaccine Segment by Type

Live-Attenuated

Inactivated

Recombinant Sub Unit and Toxoid

Disease Control and Prevention Vaccine Segment by Application

Pediatric Vaccine

Adult Vaccine

Disease Control and Prevention Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Disease Control and Prevention Vaccine status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Disease Control and Prevention Vaccine key companies, revenue, market share, and recent developments.

3. To split the Disease Control and Prevention Vaccine breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Disease Control and Prevention Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Disease Control and Prevention Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Disease Control and Prevention Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Disease Control and Prevention Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Disease Control and Prevention Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Disease Control and Prevention Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Disease Control and Prevention Vaccine industry.

Chapter 3: Detailed analysis of Disease Control and Prevention Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Disease Control and Prevention Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Disease Control and Prevention Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Disease Control and Prevention Vaccine Industry Trends Table 2. Disease Control and Prevention Vaccine Industry Drivers Table 3. Disease Control and Prevention Vaccine Industry Opportunities and Challenges Table 4. Disease Control and Prevention Vaccine Industry Restraints Table 5. Global Disease Control and Prevention Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Disease Control and Prevention Vaccine Revenue Share by Company (2021-2026) Table 7. Global Disease Control and Prevention Vaccine Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Disease Control and Prevention Vaccine Key Company Manufacturing Base & Headquarters Table 9. Global Disease Control and Prevention Vaccine Company, Product Type & Application Table 10. Global Disease Control and Prevention Vaccine Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Disease Control and Prevention Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Live-Attenuated Table 15. Significant Companies of Inactivated Table 16. Significant Companies of Recombinant Sub Unit and Toxoid Table 17. Global Disease Control and Prevention Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Disease Control and Prevention Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Disease Control and Prevention Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Disease Control and Prevention Vaccine Sales Value Share by Type (2021-2026) Table 21. Global Disease Control and Prevention Vaccine Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Pediatric Vaccine Table 23. Significant Companies of Adult Vaccine Table 24. Global Disease Control and Prevention Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Disease Control and Prevention Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Disease Control and Prevention Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Disease Control and Prevention Vaccine Sales Value Share by Application (2021-2026) Table 28. Global Disease Control and Prevention Vaccine Sales Value Share by Application (2027-2032) Table 29. Global Disease Control and Prevention Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Disease Control and Prevention Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Disease Control and Prevention Vaccine Sales Value Share by Region (2021-2026) Table 32. Global Disease Control and Prevention Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Disease Control and Prevention Vaccine Sales Value Share by Region (2027-2032) Table 34. Global Disease Control and Prevention Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Disease Control and Prevention Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Disease Control and Prevention Vaccine Sales Value Market Share by Country (2021-2026) Table 37. Global Disease Control and Prevention Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Disease Control and Prevention Vaccine Sales Value Market Share by Country (2027-2032) Table 39. GSK Company Information Table 40. GSK Business Overview Table 41. GSK Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. GSK Disease Control and Prevention Vaccine Product Portfolio Table 43. GSK Recent Development Table 44. Takeda Pharmaceutical Company Limited Company Information Table 45. Takeda Pharmaceutical Company Limited Business Overview Table 46. Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Product Portfolio Table 48. Takeda Pharmaceutical Company Limited Recent Development Table 49. Sanofi Company Information Table 50. Sanofi Business Overview Table 51. Sanofi Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Sanofi Disease Control and Prevention Vaccine Product Portfolio Table 53. Sanofi Recent Development Table 54. Johnson & Johnson Company Information Table 55. Johnson & Johnson Business Overview Table 56. Johnson & Johnson Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Johnson & Johnson Disease Control and Prevention Vaccine Product Portfolio Table 58. Johnson & Johnson Recent Development Table 59. Pfizer Company Information Table 60. Pfizer Business Overview Table 61. Pfizer Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Pfizer Disease Control and Prevention Vaccine Product Portfolio Table 63. Pfizer Recent Development Table 64. Daiichi Sankyo Company Information Table 65. Daiichi Sankyo Business Overview Table 66. Daiichi Sankyo Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Daiichi Sankyo Disease Control and Prevention Vaccine Product Portfolio Table 68. Daiichi Sankyo Recent Development Table 69. AstraZeneca PLC Company Information Table 70. AstraZeneca PLC Business Overview Table 71. AstraZeneca PLC Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. AstraZeneca PLC Disease Control and Prevention Vaccine Product Portfolio Table 73. AstraZeneca PLC Recent Development Table 74. Sinovac Biotech Ltd Company Information Table 75. Sinovac Biotech Ltd Business Overview Table 76. Sinovac Biotech Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Sinovac Biotech Ltd Disease Control and Prevention Vaccine Product Portfolio Table 78. Sinovac Biotech Ltd Recent Development Table 79. Serum Institute of India Pvt. Ltd Company Information Table 80. Serum Institute of India Pvt. Ltd Business Overview Table 81. Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Product Portfolio Table 83. Serum Institute of India Pvt. Ltd Recent Development Table 84. Panacea Biotec Ltd Company Information Table 85. Panacea Biotec Ltd Business Overview Table 86. Panacea Biotec Ltd Disease Control and Prevention Vaccine Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Panacea Biotec Ltd Disease Control and Prevention Vaccine Product Portfolio Table 88. Panacea Biotec Ltd Recent Development Table 89. Novavax Inc Company Information Table 90. Novavax Inc Business Overview Table 91. Novavax Inc Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Novavax Inc Disease Control and Prevention Vaccine Product Portfolio Table 93. Novavax Inc Recent Development Table 94. Mitsubishi Tanabe Pharma Corporation Company Information Table 95. Mitsubishi Tanabe Pharma Corporation Business Overview Table 96. Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Product Portfolio Table 98. Mitsubishi Tanabe Pharma Corporation Recent Development Table 99. Merck & Co., Inc Company Information Table 100. Merck & Co., Inc Business Overview Table 101. Merck & Co., Inc Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Merck & Co., Inc Disease Control and Prevention Vaccine Product Portfolio Table 103. Merck & Co., Inc Recent Development Table 104. Inovio Pharmaceuticals Inc Company Information Table 105. Inovio Pharmaceuticals Inc Business Overview Table 106. Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Product Portfolio Table 108. Inovio Pharmaceuticals Inc Recent Development Table 109. Emergent BioSolutions Inc Company Information Table 110. Emergent BioSolutions Inc Business Overview Table 111. Emergent BioSolutions Inc Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Emergent BioSolutions Inc Disease Control and Prevention Vaccine Product Portfolio Table 113. Emergent BioSolutions Inc Recent Development Table 114. CSL Limited Company Information Table 115. CSL Limited Business Overview Table 116. CSL Limited Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. CSL Limited Disease Control and Prevention Vaccine Product Portfolio Table 118. CSL Limited Recent Development Table 119. Bharat Biotech International Company Information Table 120. Bharat Biotech International Business Overview Table 121. Bharat Biotech International Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Bharat Biotech International Disease Control and Prevention Vaccine Product Portfolio Table 123. Bharat Biotech International Recent Development Table 124. Bavarian Nordic A/S Company Information Table 125. Bavarian Nordic A/S Business Overview Table 126. Bavarian Nordic A/S Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Bavarian Nordic A/S Disease Control and Prevention Vaccine Product Portfolio Table 128. Bavarian Nordic A/S Recent Development Table 129. Astellas Pharma Inc Company Information Table 130. Astellas Pharma Inc Business Overview Table 131. Astellas Pharma Inc Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. Astellas Pharma Inc Disease Control and Prevention Vaccine Product Portfolio Table 133. Astellas Pharma Inc Recent Development Table 134. Abbott Laboratories Company Information Table 135. Abbott Laboratories Business Overview Table 136. Abbott Laboratories Disease Control and Prevention Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Abbott Laboratories Disease Control and Prevention Vaccine Product Portfolio Table 138. Abbott Laboratories Recent Development Table 139. Research Programs/Design for This Report Table 140. Authors List of This Report Table 141. Secondary Sources Table 142. Primary Sources List of Figures Figure 1. Disease Control and Prevention Vaccine Product Image Figure 2. Global Disease Control and Prevention Vaccine Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Disease Control and Prevention Vaccine Market Size (2021-2032) & (US$ Million) Figure 4. Global Disease Control and Prevention Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Live-Attenuated Image Figure 8. Inactivated Image Figure 9. Recombinant Sub Unit and Toxoid Image Figure 10. Global Disease Control and Prevention Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Disease Control and Prevention Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Disease Control and Prevention Vaccine Sales Value Share by Type (2021-2032) Figure 13. Pediatric Vaccine Image Figure 14. Adult Vaccine Image Figure 15. Global Disease Control and Prevention Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Disease Control and Prevention Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Disease Control and Prevention Vaccine Sales Value Share by Application (2021-2032) Figure 18. Global Disease Control and Prevention Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Disease Control and Prevention Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Disease Control and Prevention Vaccine Sales Value (2021-2032) & (US$ Million) Figure 21. North America Disease Control and Prevention Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Disease Control and Prevention Vaccine Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Disease Control and Prevention Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Disease Control and Prevention Vaccine Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Disease Control and Prevention Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Disease Control and Prevention Vaccine Sales Value (2021-2032) & (US$ Million) Figure 27. South America Disease Control and Prevention Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Disease Control and Prevention Vaccine Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Disease Control and Prevention Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Live-Attenuated
  • Inactivated
  • Recombinant Sub Unit and Toxoid
Applications
  • Pediatric Vaccine
  • Adult Vaccine
Companies covered
  • GSK
  • Takeda Pharmaceutical Company Limited
  • Sanofi
  • Johnson & Johnson
  • Pfizer
  • Daiichi Sankyo
  • AstraZeneca PLC
  • Sinovac Biotech Ltd
  • Serum Institute of India Pvt. Ltd
  • Panacea Biotec Ltd
  • Novavax Inc
  • Mitsubishi Tanabe Pharma Corporation
  • Merck & Co., Inc
  • Inovio Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • CSL Limited
  • Bharat Biotech International
  • Bavarian Nordic A/S
  • Astellas Pharma Inc
  • Abbott Laboratories

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Disease Control and Prevention Vaccine Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Disease Control and Prevention Vaccine Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Disease Control and Prevention Vaccine Market Dynamics
  1. 2.1 Disease Control and Prevention Vaccine Industry Trends
  2. 2.2 Disease Control and Prevention Vaccine Industry Drivers
  3. 2.3 Disease Control and Prevention Vaccine Industry Opportunities and Challenges
  4. 2.4 Disease Control and Prevention Vaccine Industry Restraints
3 Disease Control and Prevention Vaccine Market by Company
  1. 3.1 Global Disease Control and Prevention Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Disease Control and Prevention Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Disease Control and Prevention Vaccine Company Ranking (2024-2026)
  4. 3.4 Global Disease Control and Prevention Vaccine Company Manufacturing Base and Headquarters
  5. 3.5 Global Disease Control and Prevention Vaccine Company Product Type and Application
  6. 3.6 Global Disease Control and Prevention Vaccine Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Disease Control and Prevention Vaccine Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Disease Control and Prevention Vaccine Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Disease Control and Prevention Vaccine Market by Type
  1. 4.1 Disease Control and Prevention Vaccine Type Introduction
  2. 4.1.1 Live-Attenuated
  3. 4.1.2 Inactivated
  4. 4.1.3 Recombinant Sub Unit and Toxoid
  5. 4.2 Global Disease Control and Prevention Vaccine Sales Value by Type
  6. 4.2.1 Global Disease Control and Prevention Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Disease Control and Prevention Vaccine Sales Value by Type (2021-2032)
  8. 4.2.3 Global Disease Control and Prevention Vaccine Sales Value Share by Type (2021-2032)
5 Disease Control and Prevention Vaccine Market by Application
  1. 5.1 Disease Control and Prevention Vaccine Application Introduction
  2. 5.1.1 Pediatric Vaccine
  3. 5.1.2 Adult Vaccine
  4. 5.2 Global Disease Control and Prevention Vaccine Sales Value by Application
  5. 5.2.1 Global Disease Control and Prevention Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Disease Control and Prevention Vaccine Sales Value by Application (2021-2032)
  7. 5.2.3 Global Disease Control and Prevention Vaccine Sales Value Share by Application (2021-2032)
6 Disease Control and Prevention Vaccine Regional Value Analysis
  1. 6.1 Global Disease Control and Prevention Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Disease Control and Prevention Vaccine Sales Value by Region (2021-2032)
  3. 6.2.1 Global Disease Control and Prevention Vaccine Sales Value by Region: 2021-2026
  4. 6.2.2 Global Disease Control and Prevention Vaccine Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Disease Control and Prevention Vaccine Sales Value (2021-2032)
  7. 6.3.2 North America Disease Control and Prevention Vaccine Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Disease Control and Prevention Vaccine Sales Value (2021-2032)
  10. 6.4.2 Europe Disease Control and Prevention Vaccine Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Disease Control and Prevention Vaccine Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Disease Control and Prevention Vaccine Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Disease Control and Prevention Vaccine Sales Value (2021-2032)
  16. 6.6.2 South America Disease Control and Prevention Vaccine Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Disease Control and Prevention Vaccine Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Disease Control and Prevention Vaccine Sales Value Share by Country, 2025 VS 2032
7 Disease Control and Prevention Vaccine Country-level Value Analysis
  1. 7.1 Global Disease Control and Prevention Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Disease Control and Prevention Vaccine Sales Value by Country (2021-2032)
  3. 7.2.1 Global Disease Control and Prevention Vaccine Sales Value by Country (2021-2026)
  4. 7.2.2 Global Disease Control and Prevention Vaccine Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Disease Control and Prevention Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Disease Control and Prevention Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Disease Control and Prevention Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GSK Disease Control and Prevention Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Takeda Pharmaceutical Company Limited
  8. 8.2.1 Takeda Pharmaceutical Company Limited Company Information
  9. 8.2.2 Takeda Pharmaceutical Company Limited Business Overview
  10. 8.2.3 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Pharmaceutical Company Limited Disease Control and Prevention Vaccine Product Portfolio
  12. 8.2.5 Takeda Pharmaceutical Company Limited Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Disease Control and Prevention Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Disease Control and Prevention Vaccine Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Disease Control and Prevention Vaccine Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Daiichi Sankyo
  32. 8.6.1 Daiichi Sankyo Company Information
  33. 8.6.2 Daiichi Sankyo Business Overview
  34. 8.6.3 Daiichi Sankyo Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Daiichi Sankyo Disease Control and Prevention Vaccine Product Portfolio
  36. 8.6.5 Daiichi Sankyo Recent Developments
  37. 8.7 AstraZeneca PLC
  38. 8.7.1 AstraZeneca PLC Company Information
  39. 8.7.2 AstraZeneca PLC Business Overview
  40. 8.7.3 AstraZeneca PLC Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AstraZeneca PLC Disease Control and Prevention Vaccine Product Portfolio
  42. 8.7.5 AstraZeneca PLC Recent Developments
  43. 8.8 Sinovac Biotech Ltd
  44. 8.8.1 Sinovac Biotech Ltd Company Information
  45. 8.8.2 Sinovac Biotech Ltd Business Overview
  46. 8.8.3 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sinovac Biotech Ltd Disease Control and Prevention Vaccine Product Portfolio
  48. 8.8.5 Sinovac Biotech Ltd Recent Developments
  49. 8.9 Serum Institute of India Pvt. Ltd
  50. 8.9.1 Serum Institute of India Pvt. Ltd Company Information
  51. 8.9.2 Serum Institute of India Pvt. Ltd Business Overview
  52. 8.9.3 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Serum Institute of India Pvt. Ltd Disease Control and Prevention Vaccine Product Portfolio
  54. 8.9.5 Serum Institute of India Pvt. Ltd Recent Developments
  55. 8.10 Panacea Biotec Ltd
  56. 8.10.1 Panacea Biotec Ltd Company Information
  57. 8.10.2 Panacea Biotec Ltd Business Overview
  58. 8.10.3 Panacea Biotec Ltd Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Panacea Biotec Ltd Disease Control and Prevention Vaccine Product Portfolio
  60. 8.10.5 Panacea Biotec Ltd Recent Developments
  61. 8.11 Novavax Inc
  62. 8.11.1 Novavax Inc Company Information
  63. 8.11.2 Novavax Inc Business Overview
  64. 8.11.3 Novavax Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Novavax Inc Disease Control and Prevention Vaccine Product Portfolio
  66. 8.11.5 Novavax Inc Recent Developments
  67. 8.12 Mitsubishi Tanabe Pharma Corporation
  68. 8.12.1 Mitsubishi Tanabe Pharma Corporation Company Information
  69. 8.12.2 Mitsubishi Tanabe Pharma Corporation Business Overview
  70. 8.12.3 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Mitsubishi Tanabe Pharma Corporation Disease Control and Prevention Vaccine Product Portfolio
  72. 8.12.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
  73. 8.13 Merck & Co., Inc
  74. 8.13.1 Merck & Co., Inc Company Information
  75. 8.13.2 Merck & Co., Inc Business Overview
  76. 8.13.3 Merck & Co., Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Merck & Co., Inc Disease Control and Prevention Vaccine Product Portfolio
  78. 8.13.5 Merck & Co., Inc Recent Developments
  79. 8.14 Inovio Pharmaceuticals Inc
  80. 8.14.1 Inovio Pharmaceuticals Inc Company Information
  81. 8.14.2 Inovio Pharmaceuticals Inc Business Overview
  82. 8.14.3 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Inovio Pharmaceuticals Inc Disease Control and Prevention Vaccine Product Portfolio
  84. 8.14.5 Inovio Pharmaceuticals Inc Recent Developments
  85. 8.15 Emergent BioSolutions Inc
  86. 8.15.1 Emergent BioSolutions Inc Company Information
  87. 8.15.2 Emergent BioSolutions Inc Business Overview
  88. 8.15.3 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Emergent BioSolutions Inc Disease Control and Prevention Vaccine Product Portfolio
  90. 8.15.5 Emergent BioSolutions Inc Recent Developments
  91. 8.16 CSL Limited
  92. 8.16.1 CSL Limited Company Information
  93. 8.16.2 CSL Limited Business Overview
  94. 8.16.3 CSL Limited Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  95. 8.16.4 CSL Limited Disease Control and Prevention Vaccine Product Portfolio
  96. 8.16.5 CSL Limited Recent Developments
  97. 8.17 Bharat Biotech International
  98. 8.17.1 Bharat Biotech International Company Information
  99. 8.17.2 Bharat Biotech International Business Overview
  100. 8.17.3 Bharat Biotech International Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Bharat Biotech International Disease Control and Prevention Vaccine Product Portfolio
  102. 8.17.5 Bharat Biotech International Recent Developments
  103. 8.18 Bavarian Nordic A/S
  104. 8.18.1 Bavarian Nordic A/S Company Information
  105. 8.18.2 Bavarian Nordic A/S Business Overview
  106. 8.18.3 Bavarian Nordic A/S Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Bavarian Nordic A/S Disease Control and Prevention Vaccine Product Portfolio
  108. 8.18.5 Bavarian Nordic A/S Recent Developments
  109. 8.19 Astellas Pharma Inc
  110. 8.19.1 Astellas Pharma Inc Company Information
  111. 8.19.2 Astellas Pharma Inc Business Overview
  112. 8.19.3 Astellas Pharma Inc Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Astellas Pharma Inc Disease Control and Prevention Vaccine Product Portfolio
  114. 8.19.5 Astellas Pharma Inc Recent Developments
  115. 8.20 Abbott Laboratories
  116. 8.20.1 Abbott Laboratories Company Information
  117. 8.20.2 Abbott Laboratories Business Overview
  118. 8.20.3 Abbott Laboratories Disease Control and Prevention Vaccine Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Abbott Laboratories Disease Control and Prevention Vaccine Product Portfolio
  120. 8.20.5 Abbott Laboratories Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst